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Abstract 
Background 
Liquid crystal glasses use an intermittent occlusion technique and may improve compliance 
compared to adhesive patches. Previous studies support the effectiveness of intermittent 
occlusion therapy (IO therapy) glasses for amblyopia treatment. However, objective compliance 
for these glasses has not been measured. The purpose of this study was to investigate the 
feasibility of using a microsensor to monitor objective compliance with IO therapy glasses.  
Methods 
Children 3 to ≤8 years of age with unilateral amblyopia were enrolled. All subjects had optimal 
refractive correction (if needed) for at least 5 weeks without improvement. Subjects were 
prescribed IO therapy glasses, set at 30-second opaque/transparent intervals (ie, occluded 50% of 
wear time). Wear time was prescribed according to amblyopia severity. For each patient, 
objective compliance with the IO therapy glasses was monitored by means of a microsensor.  
Results 
A total of 13 subjects returned with microsensor data. Compliance varied among and within 
individuals. General compliance averaged 51.6% (range, 10%-97%). Mean daily compliance 
decreased slightly over time. On average, patients’ visual acuity improved 0.14 ± 0.15 logMAR 
(range, −0.1 to 0.5 logMAR). No parents reported that their child had social concerns related to 
the attached microsensor. 
Conclusions 
Objective compliance with IO therapy glasses can be monitored by a simple microsensor 
reliably. In our study cohort, objective compliance with IO therapy glasses varied among 
individuals, but on average it declined slightly over time.   
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For amblyopia treatment, intermittent occlusion (IO) therapy enabled by liquid crystal 
technology glasses presents an alternative to patching. IO therapy glasses can be programmed to 
unilaterally alternate between opaque and transparent phases at 30-second intervals, providing 
effective occlusion of fellow eye 50% of the time they are worn. Previous studies have assessed 
the effectiveness of the IO therapy glasses.1-3 Because the glasses are child friendly, they can 
potentially improve compliance with occlusion. 
Previous studies have prescribed IO therapy glasses to patients with amblyopia for 
different treatment hours. Spierer and colleagues1 used IO therapy glasses with a 2:1 
occlusion/transparent ratio, prescribed at least 8 hours to children with moderate amblyopia, an 
equivalent of “at least 5.3 hours occlusion per day.” Erbagci and colleagues2 described IO 
therapy glasses with a 1:1 occlusion/transparent ratio (prescribed at least 4-12 hours to children 
with moderate and severe amblyopia) as effectively resulting in 2-6 hours occlusion per day. 
Wang and colleagues3 hypothesized that 4 hours of IO therapy would equal 2 hours of patching 
and, for IO therapy glasses with 1:1 occlusion/transparent ratio, prescribed 4 hours to children 
with moderate amblyopia. All of these studies described a benefit of IO therapy; however, there 
is no consensus with regard to how much IO therapy is needed to effectively treat amblyopia. 
Nor have previous studies objectively measured compliance with glasses wear, limiting reliable 
assessment of the dose–response relationship of IO therapy. Spierer and colleagues1 and Erbagci 
and colleagues2 estimated a high degree of compliance with prescribed use of IO therapy glasses. 
In the study of Wang and colleagues,3 however, all participants were provided with a calendar 
log to independently report compliance, which has been used in previous patching or atropine 
amblyopia treatment studies.4,5 They reported that the self-reported compliance with IO therapy 
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is similar to that of patching, in lieu of the expected higher compliance.3 Objective data on 
compliance with IO therapy glasses is lacking.  
Januschowski and colleagues6 previously used microsensors on common spectacles to 
monitor glasses wear. IO therapy glasses differ from common spectacles because the dosage of 
IO therapy may vary with periodic treatment outcome, and cumulative occlusion time is critical 
for successful treatment.7 Finding an efficient method for monitoring compliance is critical for 
both research and clinical results. The purpose of the present study was to evaluate the feasibility 
of using a microsensor to monitor compliance with IO therapy glasses in children 3 to ≤8 years 
of age with unilateral amblyopia. 
Subjects and Methods 
This research protocol and the informed consent forms were approved by the Salus University 
Institutional Review Board and complied with the US Health Insurance Portability and 
Accountability Act of 1996. Children 3 to ≤8 years of age with unilateral amblyopia from eye 
clinics in the greater Philadelphia and Chicago areas were enrolled. Informed consent was 
obtained from the subject’s parent or guardian (hereafter, “parent”); assent was also obtained 
from subjects 7-8 years of age. Eligibility testing included measurement of visual acuity in both 
eyes using the standard ATS single-surround HOTV letter protocol8 and a routine comprehensive 
eye examination (comprehensive ocular examination and a full motility examination). 
Cycloplegic refraction was completed within 6 months. Children were eligible for inclusion if 
they met the following criteria: age 3 to ≤8 years; unilateral amblyopia, that is, best-corrected 
visual acuity of the amblyopic eye ranging from 20/40 to 20/4009; interocular logMAR 
difference of at least 2 lines; visual acuity in the sound eye of at least 20/40 or better; amblyopia 
associated with strabismus, anisometropia, or both, or with post-cataract surgery; wearing of 
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optimal spectacle correction (if needed) for a minimum of 5 weeks prior to enrollment; and 
amblyopic eye either untreated by patching or atropine for at least 6 months. Subjects were not 
included if they had a known allergy to adhesives; gestational age of ≤32 weeks at birth; or 
Down syndrome or developmental delays. 
Details of the protocol for correction of refractive error followed previous PEDIG 
amblyopia treatment study guidelines.10 In brief, hyperopia was not undercorrected by more than 
+1.50 D spherical equivalent, and undercorrection in plus was symmetric in both eyes; cylinder 
power in both eyes was within 0.50 D of fully correcting the astigmatism; cylinder axis in both 
eyes was within 6° of the axis of the cycloplegic refraction; and spherical equivalent was within 
0.50 D of fully correcting the anisometropia.  
Each participant was provided a pair of rechargeable IO therapy glasses (Amblyz liquid 
crystal glasses; XPAND 3D Group, Limassol, Cyprus) with the proper prescription. Glasses 
were set at 30-second opaque/transparent intervals for the nonamblyopic fellow eye (Figure 1A).  
To independently monitor compliance, IO therapy glasses were provided with a 
TheraMon microsensor (Hargelsberg, Austria).6 It is inexpensive and commercially available. 
The microsensor is 9 × 13 mm in size, encapsulated in polyurethane, and waterproof. It does not 
cause skin irritation and carries no significant risk. The preset “headgear” software option 
allowed for external use. The microsensor was glued to the temple arm to enable detection of 
threshold temperature (Figures 1B-C). When the child wore the glasses, the microsensor was in 
direct contact with the skin and recorded body temperature every 15 minutes. During a routine 
visit, the stored data was downloaded at a reading station for analysis.6 The microsensor recorded 
all temperatures after initiation. The threshold temperature of 82°-96° F was the same for every 
child. Generally, the temperature graph shows a sudden increase of temperature when the device 
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is first worn and a sharp drop of temperature when it is removed, which was always possible to 
distinguish. A sudden increase in temperature close to the body temperature was defined as the 
starting point of the wear time; a sudden drop, as the end point.6 The period between start and 
end was counted as “wear” time. 
Participants were from two clinical trials. For clinical trial NCT02687581, patients with 
severe amblyopia who failed patching were prescribed with 12-hour IO therapy for 12 weeks. 
For clinical trial NCT02767856, patients with moderate amblyopia were randomized with 12-
hour IO therapy for 4 weeks or 4-hour IO therapy for 12 weeks. 
After a 4- or 12-week period of treatment, each participant returned for a routine follow-
up eye examination. Compliance was evaluated based on recorded wear data: compliance was 
defined as the percentage of hours glasses were worn compared to hours of wearing prescribed. 
Daily compliance was calculated, and general compliance was determined as the average of daily 
compliance for individuals. The correlation of age and compliance was calculated. Descriptive 
statistics was applied. Daily compliance was fit with linear regression. In addition, we compared 
mean objective compliance with IO therapy with patching results of Wallace and colleagues.11 
The participant’s parent was asked to comment about their child’s experiences with IO 
therapy glasses. Potential major adverse events monitored for included any injury associated 
with IO therapy glasses or the microsensor. Any loss or possible breakage was recorded. 
Results 
Between June 2016 and April 2018, 20 patients were enrolled, of whom 13 returned with 
microsensor data for analysis. Table 1 provides the basic characteristics of these patients.  
In this study, the longest period of monitoring IO therapy glasses with the mircosensor 
was about 48 weeks (approximately 9 months). Figure 2A shows an example of a patient’s daily 
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compliance with IO therapy over 48 weeks as recorded by one microsensor. Figure 2B shows an 
example of patient’s daily compliance with IO therapy over 12 weeks. Compliance varied among 
and within individuals. Figure 3 shows the mean compliance with IO therapy over 12 weeks. 
General compliance over 4 weeks was averaged at 51.6% (range, 10%-97%). Compliance varied 
among individuals, and variances were significant. Over the 3-month follow-up period, mean 
daily compliance declined slightly with time. 
Three of 13 patients had broken glasses over the treatment duration. In such cases, we 
immediately shipped them a new pair of glasses with a new microsensor, and the glasses arrived 
within one week. One patient’s parent reported that the microsensor dropped off, and the parent 
reattached it himself with superglue with our instruction. No parent reported that their children 
had social concerns related to the attached sensor or IO therapy glasses. 
Over 4-12 weeks, patients’ visual acuity improved on average 0.14 ± 0.15 logMAR 
(range, −0.1 to 0.5 logMAR). 
Discussion 
This is the first study to monitor compliance with IO therapy using a microsensor affixed to 
glasses in patients 3 to ≤8 years old with unilateral amblyopia. Compliance with IO therapy was 
not as high as we expected and varied greatly from patient to patient. Our results suggest that 
treatment guidelines and data from existing studies regarding IO therapy should be regarded 
critically. We also recommend that compliance measurements should be included in future 
research studies and clinical practice. 
Wang and colleagues3 showed that IO therapy is as effective as patching occlusion 
therapy in children with moderate amblyopia. The relative ease of use with IO therapy possibly 
leading to better compliance compared with patching was discussed. This was not supported by 
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the findings in our study.3 It seems that the occlusion of the fellow eye per se or the cosmetic 
factor associated with occlusion were the major factors influencing compliance, independent of 
the occlusion method. We do note, however, that decreasing adherence over time seems to be 
less accentuated in IO therapy subjects. This needs to be elaborated on in future studies. One 
limitation of the current study is that we compared our data to compliance with patching from 
Wallace and colleagues11 rather than a concurrent randomized control group. And although we 
did incorporate some aspects of the PEDIG protocol into our study design (eg, spectacle 
correction criteria), there remain differences in the inclusion criteria for the two studies. As a 
result, we must be cautious in interpreting the comparison.  
It could also be argued that the IO therapy glasses were only worn during the occlusion 
phases, possibly negatively affecting compliance. Adhering to the prescription of certain hours 
per day requires switching between IO therapy glasses and spectacles; this switch added some 
novel challenges for compliance. This might be improved by technical developments, for 
example, occlusion glasses that can be worn all day for refractive correction and only shutter 
during certain periods of time. 
One advantage of the microsensor is its ability to store data for up to 100 days. We 
scheduled 1-month or 3-month follow-up visits for our patients after amblyopia treatment was 
initiated. Other previous amblyopia compliance studies12,13 used monitors that had a short battery 
life, and patients had to return after a short time period. For example, Maconachie and 
colleagues13 used a glasses dose monitor to investigate compliance with glasses in children with 
amblyopia. The device cannot monitor each patient over an extended period of time. Each patient 
needed 4-5 glasses dose monitors for a 6-week study, which required very frequent visits. Tjiam 
and colleagues12 used an occlusion dose monitor, which had a battery life of around 1 week. 
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More frequent visits to the ophthalmologist may result in higher compliance, and compliance is 
significantly higher for those patients who had frequent visits.11 Compared with previous reports, 
compliance measured with the microsensor in this study may reflect actual clinical compliance 
more accurately.  
One concern related to compliance with IO therapy glasses is whether the patient wore 
spectacles before IO therapy. All patients in this study wore spectacles before they were treated 
with IO therapy glasses. Maconachie and colleagues13 found that compliance with spectacle wear 
is less than optimal, and high compliance with spectacle wear is highly associated with later 
patching compliance. Similarly, we may hypothesize that compliance with IO therapy glasses is 
related to previous spectacle wear. In this study, 3 of 13 patients had broken glasses, and 1 
patient reported that the microsensor dropped off. These events indicate that a reliable 
compliance report by the microsensor depends on the quality of the IO therapy glasses.  
It is possible that compliance was underestimated in our study. The microsensor samples 
every 15 minutes, which means that it could have not recorded 15 minutes of compliance when 
the child transitioned from wear to nonwear, or nonwear to wear, of the IO therapy glasses. On 
average, we can factor in 15 minutes of underestimation. For example, if we assume one does 
not take off the glasses during the prescribed duration, then, for a 4-hour treatment, 
underestimation could be 15 minutes / (4 hours * 60 minutes per hour) = 2%. For a 12-hour 
treatment, underestimation could be 15 minutes / (12 hours * 60 minutes per hour) = 0.3%. The 
underestimation may multiply with glasses-taking-off times (n + 1). Therefore, the 
underestimation could be 15 minutes * (n + 1) / (prescribed hours * 60). For example, for a 4-
hour treatment in which the glasses are removed 2 times, underestimation could be 15 minutes * 
(2+1) / (4 hours * 60 minutes per hour) = 6%. The more the patient takes off the glasses, the 
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more we would underestimate compliance. It may be advisable for future studies to change the 
recording intervals, especially during shorter application times. 
Of course, if children looked over the IO therapy glasses while wearing them, the 
microsensor would still record compliance. The IO therapy glasses are relatively small and tight-
fitting, however, and patients cannot easily look over them. Finally, the microsensor has 
limitations with ambient temperature. Any reading within the threshold temperature range was 
considered “wear.” Therefore, the microsensor lost accuracy if surrounding temperature is 
between 33 and 37°C (91°-99° F).6 The similar limitation (91°-99° F) was reported for the 
previous occlusion-dosage monitor.14,15 Temperatures in this range were uncommon in the 
northeastern United States during the period of the study, but it is still a potential confounder. 
Schramm and colleagues16 reported the microsensor can reliably distinguish if the sensor is worn 
when it touches the skin or if it is in the trouser pocket. Despite the limitations of our study, we 
are optimistic that monitoring glasses wear in IO therapy will lead to better understanding of 
compliance patterns in our patients and to approaches to enhance compliance and thus improve 
amblyopia treatment.  
  
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Legends 
FIG 1. A, Intermittent occlusion (IO) therapy glasses. B, Microsensor attached to left temple. C, 
Magnified view of microsensor. 
FIG 2. A, Microsensor compliance report from a 7.5-year-old boy (patient 7) who wore IO 
therapy glasses for over 9 months. This child wore a single sensor for 3 12-week follow-up 
visits; his compliance slightly decreased over time. B. Example of a microsensor compliance 
report from a 5.5-year-old boy (patient 9) who wore IO therapy glasses for 12 weeks; his 
compliance was relatively consistent after the first 10 days. 
FIG 3. The mean daily compliance over 12 weeks was fitted with linear regression. It is 
compared with the mean patching compliance in green from Wallace and colleagues.11 Error bars 
indicate standard deviation. 
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Table 1. Basic characteristics and general compliance for the first 4 weeks 
 
    Visual acuity, logMAR   
Patient Age,  
years 
Sex Amblyopia 
type 
Amblyopic 
eye 
Fellow eye Severity of 
amblyopia 
4-week 
general 
compliance, 
% 
1 7.2 M Strabismic 0.6 0.2 0.4 16 
2 4.5 M Strabismic 0.9 0.0 0.9 10 
3 7.1 F Deprivation  0.5 −0.1 0.6 97 
4 7.1 F Anisometropic  0.4 −0.1 0.5 48 
5 5.2 M Anisometropic  0.5 0.2 0.3 71 
6 6.6 F Anisometropic  0.4 0.1 0.3 90 
7 4.1 F Strabismic 0.3 0.1 0.2 40 
8 7.6 M Anisometropic  0.9 −0.1 1.0 27 
9 5.9 M Anisometropic  0.3 0.1 0.2 79 
10 5.5 M Anisometropic  0.7 0.2 0.5 48 
11 7.6 M Anisometropic  0.3 0.1 0.2 85 
12 6.5 M Anisometropic  0.6 0.1 0.5 26 
13 6.2 F Strabismic 0.4 0.1 0.3 39 
Mean ± SD 6.24 ± 1.14     0.5 ± 0.2 0.1 ± 0.1 0.5 ± 0.3 51.6 ± 29.7 
SD, standard deviation; VA, visual acuity. 
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